Sotagliflozin for Heart Failure in Type 1 Diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a medication called sotagliflozin for people who have both type 1 diabetes and heart failure symptoms. The goal is to see if it can improve how you feel and manage your heart and diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 84 years old.
- You have type 1 diabetes and either take enough insulin or have a BMI of 25 or more.
- You use a continuous glucose monitor or are willing to use one for the study.
- You have been diagnosed with heart failure or are at high risk for it, based on test results or past hospital stays.
- You have symptoms like shortness of breath that limit some activities, and your heart quality of life score is below 85.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
This study tests new treatments for people with long-standing type 1 diabetes who also have early signs of heart or kidney disease. The goal is to see if these treatments can help protect the heart and kidneys.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
This trial tests whether a diabetes medicine called empagliflozin can improve the quality of life for people who have both chronic heart failure with a weak heart pump and type 2 diabetes. It compares the effects of adding empagliflozin to your current treatments.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.